Dr Gail Tsang
/content/dam/genesiscare/headshots/au-doctor-headshots/AU_Oncology_Headshot_GA_Dr Gail Tsang.jpg

Dr Gail Tsang

Dr Gail Tsang
BHB, MBChB, FRANZCR, Radiation Oncologist

I feel privileged to offer personalised, quality care to my patients, and I strive to achieve the best possible outcomes.

Languages spoken

English, Cantonese, Mandarin



Wesley Medical Centre (Oncology)
Wesley Medical Centre (Oncology)
-27.476494536119898, 152.99746445565626
Chermside (Oncology)
Chermside (Oncology)

Clinical interests in prostate cancer, breast cancer, urological cancers, gastrointestinal (GI) cancers, lung cancer, skin cancer, and haematological malignancies.

After obtaining Bachelor of Human Biology, Bachelor of Medicine and Bachelor of Surgery, Dr Tsang undertook radiation oncology training and was awarded Fellowship of Royal Australia and New Zealand College of Radiologists. Dr Tsang was recognised for her research interests with a grant in 2005 by the New Zealand Breast Cancer Foundation.

Dr Tsang has a clinical interest in breast cancer and a subspecialty interest in prostate cancer, having completed a clinical fellowship in prostate cancer at Sunnybrook Hospital, Toronto, Canada in 2009.

As an adjunct Professor at Bond University, Dr Tsang participates in undergraduate teaching. She also teaches radiation oncology registrars.

Dr Tsang embraces multidisciplinary team (MDT) meetings to ensure best management for patients through collaboration with different specialties. She actively participates in a number of MDT meetings relating to different tumour streams, and is the Chair of The Wesley Lymphoma MDT.

She is a member of the research committee at the Brisbane practice.

Research interests

  • Breast cancer and oncology research interest

Professional memberships

  • TROG
  • ABG
  • ASBD


  • All delays before radiotherapy risk progression of Merkel cell carcinoma. Tsang G, O'Brien P, Robertson R, Hamilton C, Wratten C, Denham J. Australas Radiol. 2004 Sep;48(3):371-5.
  • Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. Morton GC, Loblaw DA, Chung H, Tsang G, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Batchelar D, Danjoux C, Szumacher E. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1299-305
  • The use of 68Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Raveenthiran S, Yaxley J, Gianduzzo T, Kua B, McEwan L, Wong D, Tsang G, MacKean J. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):385-390